FIGURE

Fig. 12

ID

ZDB-FIG-250827-45

Publication

Zhang et al., 2025 - IL-23 Receptor Agonism by Mulberroside C Activates the RASGRP1/RAS/ERK Pathway Contributing to Leukopenia Treatments

Other Figures

All Figure Page

Back to All Figure Page

Fig. 12

Verification of the ERK pathway. NB4 cells were treated with Mulberroside C (MC, 20 μM), ERK-specific inhibitor SCH772984 (SCH, 10 μM), or a combination of MC (20 μM) + SCH (10 μM). (A) Flow cytometry analysis of CD11b expression. (B) Histogram illustrating the percentage of CD11b-expressing cells across different groups. n = 3. (C) Evaluation of bactericidal activity. (D) Bacterial killing assay results are presented as histograms, showing the number of bacteria killed in each group. n = 3. Data are expressed as the mean ± SEM. **p < 0.01; ****p < 0.0001 versus corresponding control groups. ns = no significance.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Phytother. Res.